复杂2型糖尿病初级-二级整合照护模式的临床结局:非劣效随机对照试验
研究为务实性多中心非劣效随机对照试验,将复杂2型糖尿病患者按3:1分配至Beacon整合照护诊所或医院专科门诊常规照护,比较12个月HbA1c。Beacon模式在符合方案分析与意向性分析中均非劣效于常规照护,安全性指标无差异,参与者满意度更高。
要点
- Beacon整合照护模式12个月HbA1c非劣效于医院专科门诊常规照护。
- 血压、血脂及生活质量等次要结局两组无统计学或临床显著差异。
- Beacon组满意度评分显著高于常规照护组,安全性指标无差异。
核心结论
- 在复杂2型糖尿病患者中,由具有特殊兴趣的全科医生在社区提供的整合照护模式可安全达到不劣于医院专科门诊金标准的临床结局。
- 社区照护组参与者的满意度更高。
- 该照护模式的实施成本尚待进一步研究确定。
研究设计与样本
- 务实性非劣效多中心随机对照试验,按3:1比例分配至Beacon诊所或医院门诊常规照护。
- 纳入年龄18岁及以上、由全科医生转诊至医院中央转诊中心且被分诊为30天或90天内就诊的2型糖尿病患者。
- 2012年11月27日至2015年7月14日共招募352人,意向性分析样本305人(常规照护组71人,Beacon模式组234人)。
- 干预为具有特殊兴趣的全科医生在内分泌科医生监督下于初级保健中管理复杂糖尿病。
- 主要结局为招募后12个月HbA1c,非劣效界值为4.4 mmol/mol(0.4%)。
主要发现
- 符合方案分析中Beacon模式相对常规照护的HbA1c差异为-0.38 mmol/mol(95% CI -4.72, 3.96),即-0.03%(95% CI -0.43, 0.36)。
- 意向性分析中HbA1c差异为-1.28 mmol/mol(95% CI -5.96, 3.40),即-0.12%(95% CI -0.55, 0.31)。
- 12个月敏感性分析中非劣效性得以维持。
- 血压、血脂及SF-12v2和DQoL-Brief测量的生活质量等次要结局无统计学或临床显著差异。
- 安全性指标两组无差异;CSQ-8满意度评分Beacon组均值(SD)28.4(4.9)高于常规照护组25.6(4.9),p < 0.001。
关键数值与推荐
- 非劣效界值为HbA1c 4.4 mmol/mol(0.4%)。
- 主要结局为招募后12个月HbA1c。
- 意向性分析样本305人,常规照护组71人、Beacon模式组234人。
- CSQ-8满意度评分Beacon组28.4(4.9) vs 常规照护组25.6(4.9),p < 0.001。
临床怎么用
- 对复杂2型糖尿病患者,可考虑由经内分泌科医生监督培训、具有特殊兴趣的全科医生在社区提供整合照护。
- 该模式在12个月血糖控制上不劣于医院专科门诊,且未增加安全性风险。
- 社区整合照护可能提升患者满意度,可作为医院专科门诊的替代或分流选择。
- 实施时需考虑当地全科医生培训与内分泌科监督支持体系。
- 该模式的成本效益尚待进一步研究。
局限性
- 研究因性质所限仅在意向分配过程中设盲。
- 意向性分析样本中两组人数不平衡(71 vs 234),源于3:1分配比例。
- 随访主要报告12个月结局,长期结局未在本文中报告。
- 成本数据未报告,需进一步研究确定该照护模式的实施成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of the study was to determine if a Beacon model of integrated care utilising general practitioners (GPs) with special interests could achieve similar clinical outcomes to a hospital-based specialist diabetes outpatient clinic. METHODS: This pragmatic non-inferiority multisite randomised controlled trial assigned individuals with complex type 2 diabetes to care delivered by a Beacon clinic or to usual care delivered by a hospital outpatient department, in a 3:1 ratio. Owing to the nature of the study, researchers were only blinded during the allocation process. Eligible participants were aged 18 or over, had been referred by their usual GP to the hospital central referral hub with type 2 diabetes and had been triaged to be seen within 30 or 90 days. The intervention consisted of diabetes management in primary care by GPs with a special interest who had been upskilled in complex diabetes under the supervision of an endocrinologist. The primary outcome was HbA1c at 12 months post-recruitment. The non-inferiority margin was 4.4 mmol/mol (0.4%). Both per-protocol and intention-to-treat analyses are reported. RESULTS: Between 27 November 2012 and 14 July 2015, 352 individuals were recruited and 305 comprised the intention-to-treat sample (71 in usual care group and 234 in the Beacon model group). The Beacon model was non-inferior to usual care for both the per-protocol (difference -0.38 mmol/mol [95% CI -4.72, 3.96]; -0.03% [95% CI -0.43, 0.36]) and the intention-to-treat (difference -1.28 mmol/mol [95% CI -5.96, 3.40]; -0.12% [95% CI -0.55, 0.31]) analyses. Non-inferiority was sustained in a sensitivity analysis at 12 months. There were no statistically or clinically significant differences in the secondary outcomes of BP, lipids or quality of life as measured by the 12 item short-form health survey (SF-12v2) and the diabetes-related quality of life (DQoL-Brief) survey. Safety indicators did not differ between groups. Participant satisfaction on the eight-item client satisfaction questionnaire (CSQ-8) was good in both groups, but scores were significantly higher in the Beacon model group than the usual care group (mean [SD] 28.4 [4.9] vs 25.6 [4.9], respectively, p < 0.001). CONCLUSIONS/INTERPRETATION: In individuals with type 2 diabetes, a model of integrated care delivered in the community by GPs with a special interest can safely achieve clinical outcomes that are not inferior to those achieved with gold-standard hospital-based specialist outpatient clinics. Individuals receiving care in the community had greater satisfaction. Further studies will determine the cost of delivering this model of care. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12612000380897 FUNDING: The study was funded by the Australian National Health and Medical Research Council (GNT1001157).
引用
- Russell AW, Donald M, Borg SJ, et al. Clinical outcomes of an integrated primary-secondary model of care for individuals with complex type 2 diabetes: a non-inferiority randomised controlled trial. Diabetologia. 2018. PMID: 30284015. doi:10.1007/s00125-018-4740-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。